C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 27, 1996
Issued Date -
N/A
app pub date -
Aug 20, 1991
filing date -
Aug 27, 1990
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to C-terminally truncated flavivirus envelope proteins 80-81% in size which are more immunogenic than their counterpart full-length proteins. The present invention further relates to recombinant viruses which encode the truncated protein and to host cells infected therewith. Host cells express the truncated protein on their outer membrane and secrete it into the medium. The present invention further relates to vaccines for use against flavivirus infection. The vaccines include either a recombinant vaccinia virus expressing the truncated envelope protein of the present invention, and the truncated envelope protein produced by a recombinant baculovinis.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully